Previous 10 | Next 10 |
2023-03-24 16:24:16 ET Summary IDEAYA Biosciences, Inc.'s platform is synthetic lethality targeting cancer. The company has produced solid proof of concept data from multiple programs. Cash is strong, and big pharma is interested in IDEAYA Biosciences, Inc. and its work. ...
2023-03-07 06:17:50 ET IDEAYA Biosciences press release ( NASDAQ: IDYA ): Q4 GAAP EPS of -$0.50 beats by $0.06 . Revenue of $4.02M (+35.8% Y/Y) misses by $2.98M . For further details see: IDEAYA Biosciences GAAP EPS of -$0.50 beats by $0.06, revenue of $4...
IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update PR Newswire Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of December 31, 2022 is anticipated to fund planned operations into 2026 Pla...
IDEAYA Biosciences to Participate in Investor Conferences in March 2023 PR Newswire SOUTH SAN FRANCISCO, Calif. , March 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committ...
IDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 16, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company ...
IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company com...
Ideaya Biosciences ( NASDAQ: IDYA ) said it started enrollment in a phase 2 trial of darovasertib as monotherapy in neo-adjuvant and adjuvant settings in patients with primary, non-metastatic uveal melanoma (UM). UM is a type of eye cancer. In one group patients with large tu...
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma PR Newswire - Initiated Phase 2 clinical trial evaluating Darovasertib as neoadjuvant treatment of uveal melanoma ...
IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161 PR Newswire - Targeting to initiate dosing of Phase 1 clinical trial in Q1 2023 to evaluate IDE161 in patients having tumors with HRD, including BRCA1/2-mu...
Summary IDEAYA caught a bid in the back end of FY22' as investors began to take notice of advancements in its clinical pipeline. The rally seems to have flattened into the new year, so we wanted to check if there's scope for it to extend further. The company's investigational compou...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...
2024-07-08 17:30:03 ET BTIG analyst issues BUY recommendation for IDYA on July 8, 2024 03:52PM ET. The previous analyst recommendation was Buy. IDYA was trading at $39.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...